Early Phase 1 N=72 Developing a Mobile Method to Measure THC-induced Impairment
Measuring THC-induced Cognitive Impairment Using a Mobile Application
Primary: Simple Reaction Time — .365; .386; .396 Seconds
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=45 Transcranial Magnetic Stimulation (TMS) for Motor Symptoms in Psychiatric Disorders
Psychomotor Retardation · Psychomotor Slowing · Schizophrenia and Related Disorders
Primary: Number of Responders at Week 3 — 4; 9; 0; 3 responders
N/A N=44 Reactions of Older Adults Driving After Cannabis Exposure
Chronic Pain
Primary: Simulated Driving Performance Task Measuring Divided Attention — 3.42; 2.57 units on a scale
N/A N=112 Impaired Risk Awareness During Intoxication in DUI Offenders
Alcohol Use
Primary: Mean Number of Alcohol Binges — 3.36; 4.05; 2.69; 3.98 Alcohol Binges
Phase 2 N=199 The Impact and Detection of Driving Impairments Associated With Acute Cannabis Smoking
Cannabis Intoxication
Primary: Change in Composite Drive Score (CDS) From Pre-smoking Simulation — -.09; .12; .01; -.17 z-score — p=<0.001
Phase 1 N=10 Marijuana Effects on Simulated Driving Performance
Cannabis · Cannabis Use · Marijuana
Primary: Mean Peak for Standard Deviation in Lane Position (SDLP) — 1.33; 1.37; 1.42; 1.35 centimeters
Phase 2 N=14 Non-intrusive Detection of Temporary Neurologic Impairment By Opioids
Healthy
Primary: Oculo-Cognitive Addition Test (OCAT) Completion Time — 57.22; 57.22; 59.56; 58.18 seconds
Phase 2 N=80 A Study to Evaluate How VI-0521 Affect Psychomotor Performance in Healthy Overweight and Obese Subjects.
Overweight · Obesity
Primary: Measure of Psychomotor Function Using Speed and Coordination on the CogScreen Pathfinder Number (PFN) Test in Subjects Treated With Alcohol Compared to Alcohol Placebo…
N/A N=99 Cannabis Effects on Driving-related Skills of Young Drivers
Psychomotor Impairment
Primary: Psychomotor Impairment (Driving) — 3.38; -1.54 change in kph
Phase 4 N=60 Characterizing and Predicting Drug Effects on Cognition
Cognitive Deficits
Primary: Change From Baseline in COWA Unique Word Count — -0.407725385; -0.425898667; -0.412534118; -0.108298333 Word Count
Phase 4 N=18 Opiates and Benzodiazepines on Driving
Driving Behavior
Primary: SDLP — 35.2; 49.8; 50.0; 33.5 centimeters
N/A N=7 The Use of Psychomotor Vigilance Testing in the Assessment of Pediatric Obstructive Sleep Apnea
Pediatric Obstructive Sleep Apnea
Primary: Number of Participants Who Achieved Criteria of Obstructive Sleep Apnea in the PVT Assessment — 5; 2 Participants
Phase 4 N=30 Countermeasures to Reduce Sensorimotor Impairment and Space Motion Sickness Resulting From Altered Gravity Levels
Vestibular
Primary: Percent Change in Roll Tilt Perception After Exposure to Hypogravity — 27.0 percentage change
Phase 1 N=23 Differences in Cannabis Impairment and Its Measurement Due to Route of Administration
Behavioral Pharmacology of Cannabis
Primary: Tetrahydrocannabinol (THC) Concentration in Blood — 0; 1.78; 3.06; 0 ng/ml
N/A N=48 The Effects of Lower Right Limb Orthopedic Immobilization on Driving Performance
Walking Cast Right Leg Immobilisation Effects · Aircast Right Leg Immobilisation Effects
Primary: Mean Breaking Time Measured on a Driving Car Simulator — 0.58 seconds
Phase 3 N=61 Effects of Dalfampridine on Cognition in Multiple Sclerosis
Multiple Sclerosis
Primary: Symbol Digit Modalities Test — 41.18; 35.06; 45.05; 38.63 score on a scale
Phase 4 N=20 Phenytoin and Driving Safety: A Randomized, Controlled Cross-Over Study
Cognitive Measures · Driving Simulator Performance
Primary: Number of Subjects Who Had a Driving Simulator Crash Event — 2; 0 Participants — p=0.50
Phase 4 N=127 Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)
Parkinson's Disease · Motor Symptoms · Akinesia
Primary: Change From Baseline in Average Daily "Time to on" ("TTO") by Subject Diary. — 60.86; 23.72; 37.14 minutes
Phase 2 N=11 Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI
Cognition Disorder · Attention Deficit Disorder · Traumatic Brain Injury
Primary: Perceptual Organization and Processing Speed Index — 89 score on a scale
Phase 2 N=40 The Effects of Cannabidiol on the Driving Ability of Healthy Adults
Driving Performance · Cognitive Impairment · Sedation Complication
Primary: Driving Performance - Percent of Time Spent Out of Lane — 4.41; 4.34 Percent time spent driving out of lane — p=0.9460
Phase 4 N=22 Impact of Cholinesterase Inhibitors on Driving Ability in Healthy Older Adults
Mental Health · Geriatrics
Primary: Psychomotor Vigilance Test (PVT) — 302.62; 277.13 milliseconds
Phase 4 N=7 A Pilot of Methylphenidate in Mild Cognitive Impairment and Dementia Participants.
Alzheimer Dementia
Primary: Feasibility of a Virtual Multicrossover Randomized Control Trial Design as Measured my Completion Rates and Medication Compliance. — 7; 7; 7 Participants
Phase 1 N=8 Validation of the Drug Impaired Driving Scenario (DIDS) on the CRCDS-miniSim
Driving Behavior · Driving Under the Influence
Primary: Standard Deviation of Lateral Position (SDLP) — 25.490; 37.849; 33.086 cm
Phase 4 N=23 Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease
Parkinson's Disease · Gait Impairment
Primary: The Primary Outcome Measure Was Change in a Gait Stride Length Between Groups at 12 and 27 Weeks. — 107.66; 112.29; 103.35 centimeters
Phase 1 N=35 Driving Simulation to Assess Non-Sedative Effects of Tolperisone
Driving Impaired
Primary: Standard Deviation of Lateral Position (SDLP) — 29.3; 29.7; 38.6 cm of deviation of lateral position
N/A N=18 PharmacoMRI of Parkinson Disease
Parkinson's Disease
Primary: Correlation Coefficient Between UPDRS III Score and Independent Components Analysis Network Strength in Left Parietal Cortex. — 0.5869 unitless
Phase 4 N=15 Sedative-Anxiolytic Effects on Simulated Driving Performance
Psychomotor Impairment
Primary: Standard Deviation of Lane Position (SLDP) — 40.08; 37.28; 36.06; 37.61 distance (cm)
N/A N=25 Robotically Augmented Mental Practice
Stroke
Primary: MEP Amplitude — 0.813; 0.475; 0.916; 1.237 mV — p=>0.00238
Phase 4 N=30 Effects of Discontinuation of Benzodiazepine-derivative Hypnotics on Cognitive and Motor Functions in Elderly Persons
Adverse Effects
Primary: Completion Rate — 26 percentage of successful completers
N/A N=22 Medical Marijuana and Its Effects on Motor Function in People With Multiple Sclerosis
Multiple Sclerosis
Primary: Fatigue — 21; 24 % decline